Source: Sernova Corporation
February 05, 2007
Summary:
Sernova Corp. (TSX-V: SVA) announced its preliminary, preclinical animal studies have demonstrated long term survival and functioning of Sertolin, the Company's patented insulin producing cellular replacement therapy.
